Atara Biotherapeutics Q3 2026 Results: Net Loss of $2.23M, Loss Narrows
Atara Biotherapeutics reported a decrease in cash and cash equivalents to $4.1 million as of September 30, 2026, down from $8.5 million at year-end 2025. The company is currently reviewing strategic alternatives and warns that it will require substantial near-term financing to continue operations, raising concerns about its ability to fund planned operations.
- Key figure
- Net loss $2.23M